Research programme: cancer gene therapy - Advagen/GenVecAlternative Names: Cancer gene therapy research programme - Advagen/Genvec
Latest Information Update: 30 Jul 2004
At a glance
- Originator Advagen; GenVec
- Class Antineoplastics; Gene therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Jul 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 15 Jul 2002 Preclinical trials in Cancer in USA (unspecified route)